Abstract

The present invention relates to compounds useful in the preparation of diazoalkanes in general (such as diazomethane, diazoethane, diazopropane, diazobutane and homologues) and to diazomethane (CH2=N=N) in particular. The compounds chosen as the diazomethane source according to the invention also have the advantage of being water soluble. They are capable of being decomposed to diazomethane or another diazoalkane (which is allowed to bubble out of the vessel to another vessel containing a solution of reactant) and are converted to by-products that are also water-soluble.

IPC Classes  ?

• C07C 275/68 - N-nitroso ureas
• C07C 279/30 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to nitro or nitroso groups
• C07C 311/49 - Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom to nitrogen atoms
• C07C 243/08 - N-nitroso-carboxamides

Abstract

The present invention relates to a method for reducing alpha-halo ketones to alpha-halo alcohols. More specifically, the present invention is concerned with the use of isolated enzymes for reduction of alpha-halo ketones to corresponding alpha-halo alcohols. The alpha-halo alcohol is obtained in good yield from the corresponding ketone in a stereoselective manner. The reaction is conducted in the presence of an isolated enzyme or a resting cell.

IPC Classes  ?

• C12P 7/02 - Preparation of oxygen-containing organic compounds containing a hydroxy group
• C12P 13/02 - Amides, e.g. chloramphenicol
• C12P 13/22 - TryptophanTyrosinePhenylalanine3,4-Dihydroxyphenylalanine
• C12P 41/00 - Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture

Abstract

The present invention relates to the synthesis of leukotriene receptor agonist compounds and to novel intermediates employed in their preparation. Leukotriene agonists are used in the treatment of asthma, as well as other conditions mediated by leukotrienes such as inflammation and allergies. A compound of particular interest is montelukast and the present invention describes an improved process for making montelukast and similar compounds.

IPC Classes  ?

• C07D 215/18 - Halogen atoms or nitro radicals
• C07C 33/24 - Monohydroxylic alcohols containing only six-membered aromatic rings as cyclic part polycyclic without condensed ring systems
• C07C 29/32 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring increasing the number of carbon atoms by reactions without formation of hydroxy groups
• C07C 29/36 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring increasing the number of carbon atoms by reactions with formation of hydroxy groups, which may occur via intermediates being derivatives of hydroxy groups, e.g. O-metal
• C07C 29/143 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen-containing functional group of C=O containing groups, e.g. —COOH of ketones
• C07C 69/08 - Formic acid esters of dihydroxylic compounds
• C07C 45/62 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by reactions not involving the formation of C=O groups by hydrogenation of carbon-to-carbon double or triple bonds